LifeSciences BC > News > Member Announcements > Page 2

DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer

November 8, 2017
DelMar Pharmaceuticals, Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 7, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” and “the Company”), a biopharmaceutical company focused on the development of new cancer therapies, today announced the appointment of Mr. Saiid Zarrabian as interim Chief Executive Officer. “DelMar is pleased to welcome Mr. Zarrabian as interim CEO at … Continue reading DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer

Xenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

November 8, 2017
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Nov. 07, 2017 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended September 30, 2017, and provided a corporate update. Dr. Simon Pimstone, Xenon’s President and Chief Executive Officer, said, “We continue to leverage our ion channel and neurological expertise to focus … Continue reading Xenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

Merck and CDRD Announce Joint Investment in the Canadian Life Sciences Ecosystem

November 3, 2017
The Centre for Drug Research and Development (CDRD)

November 3, 2017 – Ottawa, Canada – The Canadian scientific community gathered in Ottawa this week to engage in a national dialogue on science, technology and innovation policy at the annual Canadian Science Policy Conference. Just prior to the Keynote Address at this event by the Honourable Kirsty Duncan, Minister of Science, Merck Canada Inc. … Continue reading Merck and CDRD Announce Joint Investment in the Canadian Life Sciences Ecosystem

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results and Provide Corporate Update

November 2, 2017
Xenon Pharmaceuticals

BURNABY, British Columbia, Nov. 01, 2017 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2017 third quarter financial and operating results after the close of U.S. financial markets on Tuesday, November 7, 2017. Xenon management will host a conference call and live audio webcast at … Continue reading Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results and Provide Corporate Update

Arbutus Announces Conference Call to Provide a Corporate Update and Third Quarter 2017 Financial Results

November 1, 2017
Arbutus Biopharma Corporation

VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 31, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, November 2, 2017 at 1:15 PM Pacific Time (4:15 PM Eastern Time) to discuss third quarter 2017 financial results … Continue reading Arbutus Announces Conference Call to Provide a Corporate Update and Third Quarter 2017 Financial Results

DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer

October 31, 2017
DelMar Pharmaceuticals, Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., Oct. 31, 2017 /PRNewswire/ –DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” and “the Company”), a biopharmaceutical company focused on the development of new cancer therapies, today announced the presentation of new data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics which was held October 26 – … Continue reading DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer

Third Annual National Compensation Guide for Canada’s Bio-economy Released by BioTalent Canada

October 31, 2017

OTTAWA, October 31, 2017 – Today, BioTalent Canada released its third annual National Compensation Guide, which provides the average annual salaries and benefits for 34 popular skills profiles within the Canadian bio-economy. The publication also includes a national review of job descriptions and the experience, skills and education required to effectively function in those roles. … Continue reading Third Annual National Compensation Guide for Canada’s Bio-economy Released by BioTalent Canada

SignalChem Lifesciences to Present Data on the AXL Inhibitor SLC-391 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer

October 25, 2017
SignalChem Lifesciences Corporation

• SLC-391 inhibits CT-26 tumor growth by 37% in a 15-day efficacy study whereas PD-1 antibody delayed tumor growth by 27%; • Increases in the number of NK cells and the ratio of M1/M2-polarized macrophages were evident in the SLC-391 treatment group when compared to vehicle; • In combination with anti-PD1, SLC-391 significantly prolongs survival, … Continue reading SignalChem Lifesciences to Present Data on the AXL Inhibitor SLC-391 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer

BioTalent Canada Announces Mike D’Amico of Ottawa’s Stratford Managers as new Board Chair

October 24, 2017
BioTalent Canada

MISSISSAUGA, Ontario, October 24, 2017 – Mike D’Amico, Stratford Managers Corporation’s VP and HR Practice Lead, was recently named Chair of BioTalent Canada’s Board of Directors at the organization’s Board meeting. Mr. D’Amico has served on BioTalent Canada’s board for eight years, most recently as Vice-Chair. He brings a wealth of HR experience to BioTalent … Continue reading BioTalent Canada Announces Mike D’Amico of Ottawa’s Stratford Managers as new Board Chair

Arbutus Presents HBV Data at 2017 AASLD Liver Meeting

October 24, 2017
Arbutus Biopharma Corporation

Phase 2 ARB-1467 Combination Study Starting in 4Q17 Expected IND-filings in 2018 for Two New Oral Compounds VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 24, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic solutions company, today presented results from clinical and preclinical studies of HBV therapeutic agents in … Continue reading Arbutus Presents HBV Data at 2017 AASLD Liver Meeting